• Medicine
• Published in
  Journal of clinical oncology…
  2014
• DOI:10.1200/JCO.2013.51.7433

Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.

@article{Napolitano2014OptimalDO,
  title={Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.},
  author={Mariasanta Napolitano and Giorgia Saccullo and Alessandra Malato and Delia Sprini and Walter Ageno and Davide Imberti and Doris Mascheroni and Eugenio Bucherini and Pina Gallucci and Andrea D’Alessio and Tullia Prantera and Pietro Spadaro and Stefano Rotondo and Pierpaolo di Micco and Vincenzo Oriana and Oreste Urbano and Francesco Peter Recchia and Angelo Ghirarduzzi and Lucio Lo Coco and Salvatrice Mancuso and Alessandra Casuccio and Giovam Battista Rini and Sergio Siragusa},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2014},
  volume={32 32},
  pages={
          3607-12
        }
}

• Mariasanta Napolitano, Giorgia Saccullo, +20 authors Sergio Siragusa

PURPOSE We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs. PATIENTS AND METHODS Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings: those with RVT were randomly assigned to continue LMWH for an additional 6 months (group A1) or to… CONTINUE READING

View on PubMed

Open Access

Save to Library

Create Alert

Cite